NCT00207116View on ClinicalTrials.gov

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

PHASE1CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2006

Study Completion Date

March 31, 2006

Conditions

Carcinoma, Non-Small-Cell LungNeoplasm Metastasis

Interventions

DRUG

Cetuximab

IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.

Trial Locations (1)

Unknown

Local Institution, Newark

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00207116 - An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma | Biotech Hunter | Biotech Hunter